Clinical evidence for the cardiovascular beneficts of angiotensin receptor blockers

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 7, Issue SUPPL. 1, 2006, Pages

  Nickenig, Georg ^a   Ötergren, Jan ^b   Struijker Boudier, Harry ^c  

^a SAARLAND UNIVERSITY   (Germany)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Angiotensin II receptor blockers; Cardiovascular disease continuum; Renin angiotensin aldosterone system

Indexed keywords

AMLODIPINE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; IRBESARTAN; LOSARTAN; NATEGLINIDE; RAMIPRIL; TELMISARTAN; VALSARTAN;

ANGIONEUROTIC EDEMA; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COUGHING; DIABETES MELLITUS; DISEASE COURSE; DRUG EFFICACY; DRUG TARGETING; DRUG TOLERABILITY; ENZYME INHIBITION; HEART FAILURE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; LOW DRUG DOSE; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; RECEPTOR BLOCKING; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; RISK REDUCTION; TREATMENT RESPONSE;

EID: 33748665429     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2006.017     Document Type: Article

References (52)

1. Dzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J 1991; 121:1244-63.
2. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000;355:637-45.
3. Studer R, Reínecke H, Muller B, Holtz J, Just H, Drexler H. Increased angiotensin I converting enzyme gene expression in the failing human heart. J Clin Invest 1994;94:301-10.
4. Iwai N, Shimoike H, Kinoshita M. Cardiac renin-angiotensin system in the hypertrophied heart. Circulation 1995;92:2690-6.
5. Matsubara H. Pathophysiological role of angiotensin II receptor in cardiac and renal diseases. Circ Res 1998; 83:1182-91.
6. Horuichi M, Akshita M, Dzau VJ. Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension 1999;33:613-21.
7. Unger T. Pharmacological properties of angiotensin II antagonists: examining all the therapeutic implications. JRAAS 2001;2(suppl 2):S4-S7.
8. The CONSENSUS Investigators. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-35.
9. Flather MD, Yusuf S, Køber L et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 2000;355:1575-81.
10. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.
11. The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicencre trial (the EUROPA study). Lancet 2003;362:782-8.
12. Roig E, Perez-Villa F, Morales M et al. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J 2000; 21:53-7.
13. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy: a review of the literature and pathophysiology. Ann Intern Med 1992; 117:234-42.
14. McInnes GT. Clinical advantage of valsartan. Cardiology 1999;91(Suppl 1):14-18.
15. Gibson GR. Enalapril-induced cough. Arch Intern Med 1989; 149:2701-03.
16. Os I, Bratland B, Dahlöf B et al. Female sex as an important determinant of lisinopril-induced cough. Lancet 1992; 339:372.
17. Burnier M. Angiotensin II receptor blockers. Circulation 2001;103:904-12.
18. Carey RM, Wang Z-Q. Siragy HM. Role of the angiotensin type II receptor in the regulation of blood pressure and renal function. Hypertension 2000;35:155-63.
19. Bauer JH, Reams GP. The angiotensin II type 1 receptor antagonists: a new class of antihypertensive drugs. Arch Intern Med 1995;155:1361-8.
20. Messerli FH, Weber MA, Brunner HR. Angiotensin II receptor inhibition: a new therapeutic principle. Arch Intern Med 1996;156:1957-65.
21. Pylypchuk GB. ACE inhibitor versus angiotensin II blocker induced cough and angioedema. Ann Pharmacother 1998;32:1060-6.
22. Clasen R, Schupp M, Foryst-Ludwig A et al. PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension 2005;46:137-43.
23. Dahlöf B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For End point reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
24. Lindholm LH, Ibsen H, Borch-Johnsen K et al. Risk of new-onset diabetes in the Losartan Intervention For End point reduction in hypertension study. J Hypertens 2002;20:1879-86.
25. Lithell H, Hansson L, Skoog I et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003;21:875-86.
26. Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-31,
27. Kjeldsen SE, Julius S, Weber MA, Stolt P. Main results from VALUE. In: Oparil S, Weber MA, eds. Hypertension: A Companion to Brenner and Rector's The Kidney. 2nd ed. Philadelphia, Pa: Elsevier Saunders;2005:376-80.
28. Thurmann PA, Kenedi P, Schmidt A, Harder S, Rietbrock N. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation 1998;98:2037-42.
29. Malmquist K, Kahan T, Edner M et al. Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens 2001;19:1167-76.
30. Scheen A. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. Diabetes Metab 2004;30:487-96.
31. Montalescot G, Collet JP. Preserving cardiac function in the hypertensive patient: why renal parameters hold the key. Eur Heart J 2005;26:2616-22.
32. Parving HH, Lehnert H, Brochner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8.
33. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.
34. Viberti G, Wheeldon NM, for the Microalbuminuria Reduction with Valsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus. Circulation 2002;106:672-8.
35. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
36. Keane WF, Lyle PA. Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL study. Am J Kidney Dis 2003;41(Suppl 3):S22-S25.
37. Barnett AH, Bain SC, Bouter P et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004;351:1952-61.
38. Pitt B, Segal R, Martinez FA et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997;349:747-52.
39. Pitt B, Poole-Wilson PA, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-7.
40. Cohn JN, Tognoni G, for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.
41. Pfeffer MA, Swedberg K, Granger CB et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362:759-66.
42. Wong M, Staszewsky L, Latini R et al. Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. J Am Coll Cardiol 2002;40:970-5.
43. Krum H, Carson P, Farsang C et al. Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT. Eur J Heart Fail 2004;6:937-45.
44. Pfeffer MA, McMurray JJ, Velazquez EJ et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-906.
45. Dickstein K, Kjekshus J, and the OPTIMAAL Steering Committee, for the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002;360:752-60.
46. ACC/AHA Task Force. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction - executive summary. J Am Coll Cardiol 2004;44:671-719.
47. ESC Task Force. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). Eur Heart J 2005;26:1115-40.
48. McMurray JJ, Califf R, Holman R et al. Cardiologists should care about glucose: most people with cardiovascular disease or risk factors have diabetes or significant glycaemic abnormalities. Results of screening over 39,000 subjects for NAVIGATOR [abstract]. Eur Heart J 2004;25(Suppl):239.
49. Yusuf S. From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. Am J Cardiol 2002;89:18A-26A.
50. Carson P, Massie BM, McKelvie R et al. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. J Cardiol Fail 2005;11:576-85.
51. Chaturvedi N, Sjoelie AK, Svensson A, for the DIRECT Programme Study Group. The Diabetic Retinopathy Candesartan Trials (DIRECT) Programme, rationale and study design. JRAAS 2002;3:255-61.
52. Sjolie AK, Porta M, Parving HH et al. The Diabetic Retinopathy Candesartan Trials (DIRECT) Programme: baseline characteristics. JRAAS 2005;6:25-32.